RecruitingPhase 2NCT06023862

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Studying Vulvar squamous cell carcinoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Yonsei University
Principal Investigator: JUNGYUN LEE, Ph.D.
Severance Hospital, Yonsei University Health System
Intervention: Dostarlimab(drug)
Enrollment: 198 enrolled
Eligibility: 18 years · FEMALE
Timeline: 2024 – 2029

Study locations (18)

Kurume University Hospital, Kurume, Fukuoka, Japan
Fukushima Medical University Hospital, Fukushima, Fukushima, Japan
Mie University Hospital, Tsu, Mie-ken, Japan
Tohoku University Hospital, Sendai, Miyagi, Japan
Niigata Cancer Center Hospital, Niigata, Niigata, Japan
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Tokushima University Hospital, Tokushima, Tokushima, Japan
The Jikei University Hospital, Tokyo, Tokyo, Japan
The Cancer Institute Hospital Of JFCR, Tokyo, Tokyo, Japan
University of Tsukuba Hospital, Tsukuba, ㅊ Ibaraki, Japan
National University Hospital, Singapore, Singapore
Severance Hospital, Yonsei Health System, Seoul, Seoul, South Korea
National Cancer Center, Goyang-si, South Korea
Bundang Seoul National University Hospital, Seongnam-si, South Korea
Asan Medical Center, Seoul, South Korea
+3 more locations on ClinicalTrials.gov

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06023862 on ClinicalTrials.gov

Other trials for Vulvar squamous cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Vulvar squamous cell carcinoma →

← Back to all trials